Selected Recent
Publications
As of March 10, 2006
Korn EL and Graubard BI. Analysis of Health
Surveys. New York:
John Wiley and Sons, 1999.
Korn EL, Teeter DM and Baumrind S. Using
explicit clinician preferences in nonrandomized study designs. Journal of
Statistical Planning and Inference 96: 67-82, 2001
Korn EL, Arbuck SG, Pluda
JM, Simon R, Kaplan RS, and Christian MC. Clinical trial designs for cytostatic agents: Are new approaches needed? Journal
of Clinical Oncology 19: 265-272, 2001
Korn EL, Arbuck SG, Pluda
JM, Simon R, Kaplan RS, and Christian MC. Reply to Ratain
and Stadler (letter). Journal of Clinical
Oncology 19: 3154-3155, 2001.
Freidlin B and Korn EL. A testing procedure for survival data with few
responders. Statistics in Medicine 21: 65-78, 2002.
Freidlin B, Dancey J, Korn EL, Zee B, and Eisenhauer E. Multinomial phase II trial designs (letter).
Journal of Clinical Oncology 20: 599, 2002.
Albert PS, McShane LM, and Korn EL. Design of a binary biomarker study
from the results of a pilot study. Biometrics 58: 576-585, 2002.
Graubard BI and Korn EL. Inference for superpopulation parameters using sample surveys. Statistical
Science 17: 73-96, 2002.
Korn EL, McShane LM, Troendle JF, Rosenwald A, and Simon R. Identifying pre-post
chemotherapy differences in gene expression in breast tumors: A statistical
method appropriate for this aim. British Journal of Cancer 86:
1093-1096, 2002.
Freidlin B and Korn EL. A comment on futility monitoring. Controlled Clinical
Trials 23: 355-366, 2002.
Korn EL and Graubard BI. Estimating variance
components using survey data. Journal of the Royal Statistical Society B
65:175-190, 2003
Simon RM, Korn EL, McShane LM, Radmacher MD,
Wright GW and Zhao Y. Design and Analysis of DNA Microarray
Investigations. New York:
Springer, 2003
Sotiriou C, Neo S-Y, McShane LM, Korn EL, Long
PM, Jazaeri A, Martiat P,
Fox SB, Harris AL and Liu ET. Breast cancer classification and
prognosis based on gene expression profiles from a population-based
study. PNAS 100: 10393-10398, 2003.
Korn EL, Troendle JF, McShane LM and Simon
R. Controlling the number of false discoveries: application to
high-dimensional genomic data. Journal of Statistical Planning and
Inference 124: 379-398, 2004.
Freidlin B and Korn EL. Erythropoietin to treat anaemia
in patients with head and neck cancer (letter). Lancet 353: 81,
2004.
Troendle JF, Korn EL, and McShane LM. An
example of slow convergence of the bootstrap in high dimensions. American
Statistician 58: 25-29, 2004.
Korn, EL, Freidlin, B, and George SL. Data monitoring and large
apparent treatment effects (letter). Controlled Clinical Trials 25:
67-69, 2004.
Freidlin B and Korn EL. A testing procedure for survival data with few
responders (letter). Statistics in Medicine 23: 1818-1823, 2004.
Korn EL, Habermann JK, Upender
MB, Ried T and McShane LM. Objective method of
comparing DNA microarray image analysis systems. BioTechniques
36: 960-967, 2004.
Korn EL. Nontoxicity endpoints in phase I trial
designs for targeted, non-cytotoxic agents. Journal of the National
Cancer Institute 96: 977-978, 2004.
Dodd LE, Korn EL, McShane LM, Chandramouli GVR
and Chang EY. Correcting log ratios for signal saturation in cDNA microarrays. Bioinformatics
20: 96-967, 2004.
Upender MB, Habermann
JK, McShane LM, Korn EL, Barrett JC, Difilippantonio
MJ, and Ried
T. Chromosome transfer induced aneuploidy results in complex dysregulation
of the cellular transcriptome in immortalized cancer
cells.Cancer Research 64: 6941-6949,
2004.
George S, Freidlin B and Korn EL. Strength of accumulating evidence and
data monitoring committee decision making. Statistics in Medicine 23: 2659-2672, 2004.
Korn EL, Albert PS and McShane LM. Assessing surrogates as trial endpoints
using mixed models (with discussion). Statistics in Medicine 24:163-190, 2005.
Freidlin
B and Korn EL. Testing treatment effects in the presence of competing
risks.Statistics in Medicine 24: 1703-1712, 2005.
Hunsberger
S, Rubinstein LV, Dancey J, and Korn EL. Dose
escalation trial designs based on a molecularly targeted endpoint. Statistics in Medicine 24: 2171-2181,
2005.
Rubinstein
LV, Korn EL, Freidlin B, Hunsberger SA, Ivy P, and Smith MA.
Randomized phase 2 design issues and a proposal for phase II screening trials,
Journal of Clinical Oncology 23: 7199-7206, 2005.
Korn EL, Hunsberger S, Freidlin B,
Smith MA, and Abrams JS. Preliminary data release for randomized clinical trials of
noninferiority: a new proposal.Journal of Clinical Oncology 23:
5831-5836, 2005.
Korn EL and Freidlin B. (in press) The likelihood as statistical evidence
in multiple comparisons in clinical trials: no free lunch.Biometrical
Journal
brb@linus.nci.nih.gov